Herantis Pharma Plc announcing start of recruitment of healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096
Herantis Pharma PlcPress release, 4 July 2023 at 12:05 p.m. EEST Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, is now starting recruiting healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096. In part 2, 12-16 older and elderly healthy volunteers will be administered with a single dose of HER-096 to evaluate the blood-brain-barrier penetration of HER-096 in addition the safety and tolerability. The HER-096 investigational medicinal product will be administered as a